DocMorris AG (OTCMKTS:ZRSEF – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,072,637 shares, an increase of 66.8% from the July 15th total of 643,190 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.
DocMorris Price Performance
Shares of OTCMKTS:ZRSEF opened at $7.45 on Monday. The firm’s 50 day simple moving average is $7.45 and its two-hundred day simple moving average is $7.45. DocMorris has a 1-year low of $7.45 and a 1-year high of $42.50.
Wall Street Analysts Forecast Growth
ZRSEF has been the topic of several recent research reports. UBS Group upgraded shares of DocMorris from a “sell” rating to a “neutral” rating in a research note on Monday, July 20th. Deutsche Bank Aktiengesellschaft upgraded DocMorris from a “hold” rating to a “buy” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.
About DocMorris
DocMorris is a leading European online pharmacy brand and a subsidiary of the Swiss-based Zur Rose Group (OTCMKTS:ZRSEF). Through its digital platform, the company offers mail-order dispensing of prescription medications and over-the-counter health products directly to consumers’ homes.
The company’s core services include the online sale and delivery of prescription and non-prescription drugs, health supplements, personal care items and medical devices. Leveraging its e-commerce infrastructure and proprietary pharmacy management systems, DocMorris also provides digital health solutions such as telemedicine consultations, medication management tools and mobile app-based healthcare services.
Originally launched in the early 2000s in Germany, DocMorris has expanded its reach to serve customers in multiple European countries, including the Netherlands, Belgium, Luxembourg and Switzerland.
See Also
- Five stocks we like better than DocMorris
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for DocMorris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocMorris and related companies with MarketBeat.com's FREE daily email newsletter.
